Clinical Trials Logo

Allergic Fungal Rhinosinusitis clinical trials

View clinical trials related to Allergic Fungal Rhinosinusitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05545072 Recruiting - Clinical trials for Allergic Fungal Rhinosinusitis

Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

ADAPT
Start date: October 26, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS). Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages. Despite appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery, nasal polyps return frequently within months of surgery. Certain proteins made by the body called interleukins, appear to play a major role in the survival and activation of eosinophils. Antibodies are proteins naturally produced by your body that find foreign substances such as bacteria, fungi, viruses, and other substances that enter your body and make them inactive. Dupilumab is an antibody made in the laboratory that has been made to block specific interleukins from activating the eosinophils. This research is being done to find out if the medication dupilumab is effective and safe when used to treat patients with AFRS following recommended sinus surgery. Dupilumab is already approved for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP); however, it is not approved to treat AFRS. Therefore its use in this study is considered experimental.